The excipients specialist shares findings from its research into the ins and outs of 3D powder bed printed tablets and how it can benefit drug development.
The pjarmaceutical excipient, intended for use in the formulation of flash orally dissolving tablets, is designed to disintegrate in less than 10 seconds.
A leader from the excipients firm discusses how ODTs appeal to seniors and patients on the go, and the formulation-related challenges with such tablets.
A representative from Clarivate explains how supply chain vulnerabilities can hurt stakeholders, including patients—and how one solution can close the gap.
This month’s roundup of equipment, decentralized technology, partnerships and other items includes news from Medidata, PerkinElmer, Syneos and other firms.
An industry study from the producer of CPhI North America shows the pandemic and other factors are contributing to a very dynamic pharmaceutical market.
The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.
A leader from the company says to ensure medicines keep reaching the patients that need them, the industry must revamp outdated technologies and techniques.
The two companies are collaborating to research, develop and launch new small-molecule drug candidates aimed at treating obesity and related comorbidities.
A leader from the topical solutions centered CDMO discusses the differences between approaches by the FDA and EMA, and how to deal with them effectively.
A clinical trial logistics expert discusses specialized concerns involved in transporting cell and gene products and other personalized medicine items.
An expert speaking during the industry event offers insight and perspective on the flurry of CDMO deal-making in recent months, and what might lie ahead.
Contract data analysis can help predict pharma demand: Agiloft
The process management solutions firm says drug companies could use contract data to get a better handle on predicting demand and adjusting product output.
The past several days have seen a relatively large number of industry acqusitions, with Lilly, Phillip Morris, WCG, CTI and others making notable buys.
